指南与共识乳腺癌头颈与中枢神经肿瘤

晚期人表皮生长因子受体2阳性乳腺癌及脑转移的管理:ASCO指南更新

Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline Update.
指南 / 共识 · J Clin Oncol · 2022-05-31

该指南更新由专家小组对545篇文献进行针对性系统综述,其中6篇关于全身治疗的研究构成脑转移全身治疗推荐的证据基础。推荐脑转移患者接受适当的局部治疗和全身治疗,局部治疗包括手术、全脑放疗和立体定向放射外科,全脑放疗时可加用美金刚和海马回避。

要点

  • 脑转移患者应接受适当的局部治疗和全身治疗(如有指征)。
  • 局部治疗包括手术、全脑放疗和立体定向放射外科;全脑放疗时尽可能加用美金刚和海马回避。
  • 不推荐常规MRI筛查脑转移的证据不足,但临床医生应保持低阈值进行脑MRI检查。

核心结论

  • 脑转移患者应接受适当的局部治疗和全身治疗(如有指征)。

研究设计与样本

  • 专家小组对545篇文献进行针对性系统综述,其中6篇关于全身治疗的研究构成脑转移全身治疗推荐的证据基础。

主要发现

  • 共识别并综述545篇文献,其中6篇关于全身治疗的研究构成脑转移全身治疗指南推荐的证据基础。

关键数值与推荐

  • 局部治疗包括手术、全脑放疗和立体定向放射外科。
  • 全脑放疗时尽可能加用美金刚和海马回避。
  • 治疗选择取决于患者预后、症状、可切除性、转移灶数量和大小、既往治疗以及转移是否弥漫等因素。
  • 其他选择包括全身治疗、最佳支持治疗、参加临床试验和/或姑息治疗。
  • 不推荐常规MRI筛查脑转移的证据不足;临床医生应保持低阈值进行脑MRI检查,因为HER2阳性晚期乳腺癌患者脑转移发生率高。

临床怎么用

  • 脑转移患者应接受适当的局部治疗和全身治疗(如有指征)。
  • 全脑放疗时尽可能加用美金刚和海马回避。
  • 临床医生应保持低阈值进行脑MRI检查。

局限性

  • 不推荐常规MRI筛查脑转移的证据不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To provide updated evidence- and consensus-based guideline recommendations to practicing oncologists and others on the management of brain metastases for patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer up to 2021. METHODS: An Expert Panel conducted a targeted systematic literature review (for both systemic therapy for non-CNS metastases and for CNS metastases of HER2+ guideline updates) that identified 545 articles. Outcomes of interest included overall survival, progression-free survival, and adverse events. RESULTS: Of the 545 publications identified and reviewed, six on systemic therapy were identified to form the evidentiary basis for the systemic therapy for CNS metastases guideline recommendations. RECOMMENDATIONS: Patients with brain metastases should receive appropriate local therapy and systemic therapy, if indicated. Local therapies include surgery, whole-brain radiotherapy, and stereotactic radiosurgery. Memantine and hippocampal avoidance should be added to whole-brain radiotherapy when possible. Treatments depend on factors such as patient prognosis, presence of symptoms, resectability, number and size of metastases, prior therapy, and whether metastases are diffuse. Other options include systemic therapy, best supportive care, enrollment onto a clinical trial, and/or palliative care. There are insufficient data to recommend for or against performing routine magnetic resonance imaging to screen for brain metastases; clinicians should have a low threshold for magnetic resonance imaging of the brain because of the high incidence of brain metastases among patients with HER2-positive advanced breast cancer.Additional information is available at www.asco.org/breast-cancer-guidelines.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Ramakrishna N, Anders CK, Lin NU, et al. Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline Update. J Clin Oncol. 2022. PMID: 35640075. doi:10.1200/JCO.22.00520

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。